BiologicalDrug
Efgartigimod alfa clinical trials
Also written Efgartigimod, ARGX-113 and Vyvgart.
- studies test it
- 65
- open now
- 26
- in phase 3
- 30
- first study started
- 2015
Keep track of what changes. Save the efgartigimod alfa studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
64 studies that test it; most in 2025 (13); 1 more planned to start later
| Year | Studies |
|---|---|
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 3 |
| 2018 | 1 |
| 2019 | 3 |
| 2020 | 6 |
| 2021 | 7 |
| 2022 | 2 |
| 2023 | 9 |
| 2024 | 12 |
| 2025 | 13 |
| 2026 | 6 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 7
- Phase 2
- 28
- Phase 3
- 30
- Phase 4
- 5
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 47 · Other 18
argenx (47) · Shanghai Zhongshan Hospital (2) · Stanford University (1) · Beijing Tiantan Hospital (1) · M. Peter Marinkovich (1) · University of South Florida (1) · Zhongming Qiu (1) · First Affiliated Hospital of Wenzhou Medical University (1)
Often tested with
Tested in the same studies.
Hyaluronidase (human recombinant) (23) · Thymectomy (1) · Telitacicept (1) · Methylprednisolone (1)
Studies
Open first, then newest update. How each study uses efgartigimod alfa is read from its arms, and is right about nine times in ten.
Testing it · 65
- Efgartigimod in IVIG Dependent Myasthenia Gravis PatientsRecruitingPhase 3Clinique Neuro-OutaouaisNCT06765161Written as efgartigimod administration
- A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory MyopathyEnrolling by invitationPhase 3argenxNCT05979441Written as Efgartigimod PH20 SC
- A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP)RecruitingPhase 2/3argenxNCT07194850Written as Efgartigimod IV
- A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' DiseaseRecruitingPhase 3argenxNCT07570316Written as Efgartigimod PH20 SC
- A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease.RecruitingPhase 3argenxNCT07596849Written as efgartigimod PH20 SC
- A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia GravisRecruitingPhase 2/3argenxNCT06392386Written as Efgartigimod PH20 SC
- A Study to Learn About How Well the Medicine Efgartigimod Works to Treat Autoimmune Encephalitis In Children 12 Years or Older and AdultsNot yet recruitingPhase 2argenxNCT07583641Written as Efgartigimod PH20 (ARGX-113) SC
- Efficacy and Safety of Efgartigimod in the Treatment of Guillain-Barré Syndrome(GREAT)Not yet recruitingPhase 2Beijing Tiantan HospitalNCT07806916Written as Efgartigimod Alfa-Fcab
- Efgartigimod in Anti-NMDA Receptor Encephalitis.RecruitingPhase 2Beijing Tongren HospitalNCT07822776Written as Efgartigimod Alfa
- Evaluate the Benefit of Corticoid Sparing in Elderly With Generalized AntiRAch Myasthenia Gravis Treated With IV or SC EfgartigimodRecruitingPhase 4Centre Hospitalier Universitaire de NiceNCT07072988Written as Efgartigimod
- A Study to Assess Efficacy and Safety of Efgartigimod in Adults With Sjogren's Disease-associated Sensorimotor Polyneuropathy or Sensory Polyneuropathy (SERENITY)Not yet recruitingPhase 2argenxNCT07760818Written as efgartigimod PH20 SC
- A Pilot Study of Efgartigimod for Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP)RecruitingPhase 2University of MinnesotaNCT06831058Written as efgartigimod
- Targeting Collagen VII Antibodies in Bullous Diseases Using Efgartigimod IV (VYVGART)Not yet recruitingPhase 1/2M. Peter MarinkovichNCT07011589Written as Efgartigimod
- A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune ThrombocytopeniaRecruitingPhase 3argenxNCT06544499Written as Efgartigimod IV
- A Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adults With New-onset Generalized Myasthenia Gravis (gMG)RecruitingPhase 4argenxNCT06909214Written as Efgartigimod PH20 SC
- Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia GravisRecruitingPhase 2/3argenxNCT04833894Written as Efgartigimod IV
- EFG vs IVIG in TAMGNot yet recruitingPhase 3Shanghai Zhongshan HospitalNCT07231523Written as Efgartigimod + Thymectomy
- Efgartigimod for the Treatment of Acute Optic NeuritisRecruitingPhase 2Anastasia Vishnevetsky, MD, MPHNCT06453694Written as Efgartigimod Alfa
- Treatment of Myasthenia Gravis Exacerbation or Crisis With EfgartigimodRecruitingPhase 4University of Colorado, DenverNCT06860633Written as Efgartigimod
- Efgartigimod for Stiff Person Syndrome (ESPS)Not yet recruitingPhase 2University of South FloridaNCT06528392Written as Efgartigimod
See all 65 studies that test efgartigimod alfa →
Given in every arm · 1 — efgartigimod alfa is usual care beside what is tested
As the comparator · 1 — what is tested is compared with efgartigimod alfa
Codes
What other systems call efgartigimod alfa · ClinicalTrials.gg INT001674
- MeSH (NLM) C000718373efgartigimod alfaConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 961YV2O515EFGARTIGIMOD ALFAConfirmed FDA, NLM, Wikidata
- RxNorm 2587717One source FDA
- Wikidata Q110271677efgartigimod alfaConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C171817Efgartigimod AlfaOne source FDA
- DrugBank DB15270One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000718373 | efgartigimod alfa | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 961YV2O515 | EFGARTIGIMOD ALFA | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2587717 | — | One source FDA |
| Wikidata | Q110271677 | efgartigimod alfa | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C171817 | Efgartigimod Alfa | One source FDA |
| DrugBank | DB15270 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.